European Pharmaceutical Review

JANUARY 18, 2024

Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia market is anticipated to grow at a compound annual growth rate (CAGR) of 2.6 percent from $3.2 billion in 2022 to $4.1

Drug Pricing 98

Drug Pricing Biosimilars Compounding 98

Pharmaceutical Technology

JUNE 30, 2025

The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding. The facility will be complete and ready for media fill by late 2029, with plans to move Vetter’s existing clinical operations in Skokie. How will RFK Jr’s American dream for vaccines play out?

Packaging 52

Packaging Hospitals Compounding Communication 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. The primary manufacturer of a selected drug may also request CMS to terminate its agreement if they are unwilling to participate in the Medicare Drug Price Negotiation.

Labelling 105

Labelling Drug Pricing Compounding Payment Processing 105